Marken Commissions New and Expanded London Operational Hub
Marken announced that it has completed all commissioning work for its new operational hub in Feltham, UK. The new location at 648 River Gardens in Feltham is within 4 miles (6 KM) of Heathrow Airport and part of the North Feltham Trading Estate Industrial Center.
The 18.5k sq ft facility is completely occupied by Marken operational personnel and will be one of the company’s flagship facilities joining an expanding network. The facility is equipped with space for product staging, re-icing, automatic scanning, quarantined goods, secure storage for dangerous goods, import and export operations and IT support. It will also have ample office space for the London branch operations which also has responsibility for all clients operating within the UK and Ireland.
“This new facility is in direct response to recent expansion requirements in the UK to support our growing client base”, said CEO, Wes Wheeler. “We have designed this facility to accommodate all of the needs of the life science industry including inbound shipments of clinical samples and outbound shipments of drug product, active pharmaceutical ingredients and patient kits. We have allowed ample room for growth and for expanded services. We are very excited to be upgrading our facilities in the UK.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
